Laura L.
- Country
- Italy
- Department
- 2551: Ambulatorio di Allergologia Dermatologica U.O.C. Dermatologia
Research Overview
- A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled by H1-antihistamines followed by an optional open-label extension for up to another 3 years and an optional safety long-term treatment-free follow-up period for up to an additional 3 years.
- Evaluation of Lebrikizumab Efficacy and Safety in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Phase 3 Randomized Study
- A global, multicenter, randomized, double-blind, double-dummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.
Data & Insights
Has run more than one trial at 21 of 136 partner sites.
Specializations
Dermatological Research
Focused on investigating therapeutic solutions for Chronic Spontaneous Urticaria (CSU), particularly in patients showing inadequate response to conventional treatments.
- Antihistamine-resistant urticaria management
- Long-term urticaria control
- Novel therapeutic approaches
Specializes in evaluating innovative treatments across different age groups, including both adult and adolescent populations.
Clinical Assessment
Expert in evaluating therapeutic efficacy through specialized measurement tools including UAS7, ISS7, and HSS7 scoring systems for urticaria assessment.
- Treatment response metrics
- Safety evaluation protocols
- Tolerability assessments
Conducts comprehensive evaluations of both short-term and extended treatment outcomes in dermatological conditions.
Therapeutic Development
Investigates BTK inhibitor therapies for dermatological conditions, with particular focus on remibrutinib as a treatment option.
- Novel drug development
- Pharmacokinetic studies
- Treatment-resistant conditions
Specializes in comparing innovative therapies against established treatments and placebo controls.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.